文献速递乳腺癌

新辅助治疗乳腺癌中循环肿瘤DNA反映疗效与生存

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
PubMed 文献 · Ann Oncol · 2020-11-21

该研究基于I-SPY 2试验中84例高危早期乳腺癌患者,采用个体化ctDNA检测纵向监测新辅助化疗期间及术前的血浆样本。结果显示ctDNA未清除显著预测疗效差和转移复发,而清除者即使未达pCR预后也良好。

要点

  • 新辅助化疗期间ctDNA持续阳性与残留病灶风险升高相关(OR 4.33,P=0.012)。
  • 术后ctDNA阳性者转移复发风险显著增加(HR 10.4,95%CI 2.3-46.6)。
  • 未达pCR但ctDNA阴性者预后与pCR者相似,提示ctDNA可细化pCR作为替代终点。

核心结论

  • ctDNA未清除是新辅助化疗反应差和转移复发的显著预测因素,而清除与生存改善相关,即使未达pCR。

研究设计与样本

  • 研究纳入I-SPY 2试验中84例高危早期乳腺癌患者,接受标准新辅助化疗或联合MK-2206治疗。
  • 从291份血浆样本中提取cfDNA,采用基于全外显子测序的个体化ctDNA检测(最多16个突变)进行超深度测序。
  • 血液采集时间点为治疗前(T0)、紫杉醇开始后3周(T1)、紫杉醇与蒽环类之间(T2)及术前(T3),生存分析中位随访4.8年。

主要发现

  • T0时84例中61例(73%)ctDNA阳性,随后下降:T1为35%,T2为14%,T3为9%。
  • T1时持续ctDNA阳性者非pCR比例83%,而ctDNA清除者非pCR比例52%(OR 4.33,P=0.012)。
  • 新辅助化疗后达pCR者(n=17)全部ctDNA阴性(100%)。
  • 未达pCR者中(n=43),ctDNA阳性者(14%)转移复发风险显著升高(HR 10.4;95%CI 2.3-46.6)。
  • 未达pCR但ctDNA阴性者(86%)预后与达pCR者相似(HR 1.4;95%CI 0.15-13.5)。

临床怎么用

  • 在高危早期乳腺癌新辅助治疗中,个体化ctDNA动态监测可实时评估治疗反应。
  • ctDNA清除情况有助于识别未达pCR但预后良好者,辅助细化pCR作为生存替代终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is strongly associated with favorable outcome. We examined the utility of serial circulating tumor DNA (ctDNA) testing for predicting pCR and risk of metastatic recurrence. PATIENTS AND METHODS: Cell-free DNA (cfDNA) was isolated from 291 plasma samples of 84 high-risk early breast cancer patients treated in the neoadjuvant I-SPY 2 TRIAL with standard NAC alone or combined with MK-2206 (AKT inhibitor) treatment. Blood was collected at pretreatment (T0), 3 weeks after initiation of paclitaxel (T1), between paclitaxel and anthracycline regimens (T2), or prior to surgery (T3). A personalized ctDNA test was designed to detect up to 16 patient-specific mutations (from whole-exome sequencing of pretreatment tumor) in cfDNA by ultra-deep sequencing. The median follow-up time for survival analysis was 4.8 years. RESULTS: At T0, 61 of 84 (73%) patients were ctDNA positive, which decreased over time (T1: 35%; T2: 14%; and T3: 9%). Patients who remained ctDNA positive at T1 were significantly more likely to have residual disease after NAC (83% non-pCR) compared with those who cleared ctDNA (52% non-pCR; odds ratio 4.33, P = 0.012). After NAC, all patients who achieved pCR were ctDNA negative (n = 17, 100%). For those who did not achieve pCR (n = 43), ctDNA-positive patients (14%) had a significantly increased risk of metastatic recurrence [hazard ratio (HR) 10.4; 95% confidence interval (CI) 2.3-46.6]; interestingly, patients who did not achieve pCR but were ctDNA negative (86%) had excellent outcome, similar to those who achieved pCR (HR 1.4; 95% CI 0.15-13.5). CONCLUSIONS: Lack of ctDNA clearance was a significant predictor of poor response and metastatic recurrence, while clearance was associated with improved survival even in patients who did not achieve pCR. Personalized monitoring of ctDNA during NAC of high-risk early breast cancer may aid in real-time assessment of treatment response and help fine-tune pCR as a surrogate endpoint of survival.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2020. PMID: 33232761. doi:10.1016/j.annonc.2020.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。